In breast cancer, high expression of GLS and low expression of glutamate-oxaloacetate transaminase 2 (GOT2) correlate positively with the presence of DCs and suggest an enhanced response to immunotherapy (Yang et al. 2024b). The gene discussed is GOT2; the disease is breast cancer.